Predictive Presymptomatic Testing Market by Application and Geography - Forecast and Analysis 2022-2026

The predictive presymptomatic testing market share is expected to increase to USD 2.45 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.6%.

The report extensively covers predictive presymptomatic testing market segmentations by the following:

• Application - Cancer diseases, genetic diseases, and cardiovascular diseases
• Geography - North America, Europe, Asia, and Rest of World (ROW)).

The predictive presymptomatic testing market report offers information on several market vendors, including 23andMe Inc., Abbott Laboratories, Amgen Inc., BioAxis DNA Research Centre P Ltd., Color Genomics Inc., Deep Genomics, Direct Laboratory Services LLC, DNA and U, Editas Medicine Inc., Healius Ltd., Illumina Inc., International Business Machines Corp., Mapmygenome India Ltd., myDNA Life Ltd., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics Inc., Sysmex Corp., and Veritas Genetics Inc. among others.

This predictive presymptomatic testing market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches.

What will the Predictive Presymptomatic Testing Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Predictive Presymptomatic Testing Market Size for the Forecast Period and Other Important Statistics

 

Predictive Presymptomatic Testing Market: Key Drivers, Trends, and Challenges

The increasing healthcare spending worldwide is notably driving the predictive presymptomatic testing market growth, although factors such as the high cost of tests may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the predictive presymptomatic testing industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Predictive Presymptomatic Testing Market Driver

The increasing healthcare spending worldwide is one of the key drivers supporting the predictive presymptomatic testing market growth. ???????The governments of developed nations such as the US, Germany, and others have increased their healthcare expenditure in recent years. Through the support of the governments and a surge in healthcare expenditures, the global private and public healthcare facilities and not-for-profit organizations (NPOs) are able to provide their services to the patients. According to The World Health Organization (WHO), global spending on healthcare continually rose between 2000 and 2018 and reached $ 8.3 trillion or 10% of global GDP. Thus, the increasing expenditure in the global healthcare sector and the increase in government aid to healthcare providers will boost the growth of the global predictive presymptomatic testing market during the forecast period.

Key Predictive Presymptomatic Testing Market Trend

The growing prevalence of genetic diseases is one of the key predictive presymptomatic testing market trends that is contributing to the market growth. According to the Centers for Disease Control and Prevention (CDC), in the US, more than 1.6 million patients are getting diagnosed with cancer every year, with almost 600,000 fatalities. The incidence of genetic disorders is gradually increasing. Moreover, the increasing incidence of chronic diseases and genetic disorders leads researchers and scientists to opt for predictive presymptomatic testing for diagnosing and treating patients. Researchers are increasingly focusing on predictive presymptomatic testing due to its high impact on diagnosing and treating diseases using gene therapy and recombinant vaccines. Hence, an increase in the prevalence of genetic disorders is expected to drive the growth of the global predictive presymptomatic testing market during the forecast period.

Key Predictive Presymptomatic Testing Market Challenge

The high cost of tests is one of the factors hindering the predictive presymptomatic testing market growth. For instance, in 2019, the per capita healthcare expenditure was $7,138 in Switzerland, $6,748 in Norway, and $6,731 in Germany. Additionally, in developing countries such as India, China, and others, due to lack of resources and low per capita income, patients are unable to avail themselves of predictive presymptomatic test kits. The absence of proper healthcare infrastructure and less amount of government aid received in the form of medical expense reimbursement further acts as a challenge for the patients in these countries. Thus, the global per capita healthcare cost is expected to increase during the forecast period. This will negatively affect the growth of the global predictive presymptomatic testing market during the forecast period.

This predictive presymptomatic testing market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Who are the Major Predictive Presymptomatic Testing Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• 23andMe Inc.
• Abbott Laboratories
• Amgen Inc.
• BioAxis DNA Research Centre P Ltd.
• Color Genomics Inc.
• Deep Genomics
• Direct Laboratory Services LLC
• DNA and U
• Editas Medicine Inc.
• Healius Ltd.
• Illumina Inc.
• International Business Machines Corp.
• Mapmygenome India Ltd.
• myDNA Life Ltd.
• Myriad Genetics Inc.
• NeoGenomics Laboratories Inc.
• Quest Diagnostics Inc.
• Sysmex Corp.
• Veritas Genetics Inc.

 

This statistical study of the predictive presymptomatic testing market encompasses successful business strategies deployed by the key vendors. The predictive presymptomatic testing market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• 23andme.com - The company offers predictive presymptomatic testing such as BRCA1 and BRCA2 which helps in repairing DNA breaks that can lead to cancer.
• Abbott.com - The company offers predictive presymptomatic testing such as Vysis CEP 8 SpectrumOrange Direct Labeled Fluorescent DNA Probe Kit and Vysis CEP 12 SpectrumOrange Direct Labeled Fluorescent DNA Probe Kit.
• Color.com - The company offers predictive presymptomatic testing such as Hereditary Cancer Test which helps reduce risk of developing cancer.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The predictive presymptomatic testing market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Predictive Presymptomatic Testing Market?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market's growth will originate from North America during the forecast period. The US is the key market for the predictive presymptomatic testing market in North America. Market growth in this region will be slower than the growth of the market in Asia.

The increasing prevalence of multiple types of cancer will facilitate the predictive presymptomatic testing market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the COVID-19 pandemic had a negative impact on the regional predictive presymptomatic testing market. However, in 2021, due to the availability of COVID-19 vaccines, the number of COVID-19 cases in the region declined. Thus, restoration of access to hospitals, clinics, and diagnostic laboratories led to a higher frequency of predictive presymptomatic testing. Thus, the regional demand for predictive presymptomatic testing kits rebounded. Due to these factors, the regional predictive presymptomatic testing market will have a positive impact during the forecast period.

What are the Revenue-generating Application Segments in the Predictive Presymptomatic Testing Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The predictive presymptomatic testing market share growth by the cancer diseases segment will be significant during the forecast period. Cancer is usually not considered a genetic disorder. However, certain types of cancers, such as breast, ovarian, and other cancers are strongly influenced by genes. These types of cancers are passed on to the next generation. Thus, predictive and presymptomatic testing is used for the diagnosis of hereditary-based cancers such as breast and ovarian cancer. Healthy female mutation carriers of BReast CAncer (BRCA) genes have a high risk of acquiring breast cancer and ovarian cancer. Thus, the growing prevalence of breast, prostate, and ovarian cancer globally is one of the major drivers for the use of predictive and presymptomatic tests for the diagnosis of these cancers. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the predictive presymptomatic testing market size and actionable market insights on post COVID-19 impact on each segment.

Parent Market Analysis

Technavio categorizes the global predictive presymptomatic testing market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the predictive presymptomatic testing market during the forecast period.

Predictive Presymptomatic Testing Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the predictive presymptomatic testing market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Predictive Presymptomatic Testing Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 9.6%
Market growth 2022-2026	$ 2.45 billion
Market structure	Fragmented
YoY growth (%)	8.8
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 40%
Key consumer countries	US, Germany, UK, France, and Japan
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	23andMe Inc., Abbott Laboratories, Amgen Inc., BioAxis DNA Research Centre P Ltd., Color Genomics Inc., Deep Genomics, Direct Laboratory Services LLC, DNA and U, Editas Medicine Inc., Healius Ltd., Illumina Inc., International Business Machines Corp., Mapmygenome India Ltd., myDNA Life Ltd., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics Inc., Sysmex Corp., and Veritas Genetics Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Predictive Presymptomatic Testing Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive predictive presymptomatic testing market growth during the next five years
• Precise estimation of the predictive presymptomatic testing market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the predictive presymptomatic testing industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of predictive presymptomatic testing market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch